Document is current
Any future updates will be listed below
-
Authors
Mamoei, Sepehr https://orcid.org/0000-0003-3140-4983
Möller, Sören
Magyari, Melinda
Sellebjerg, Finn
Frederiksen, Jette L.
Svendsen, Kristina B.
Saleem, Rasha
Søndergaard, Helle B.
Nilsson, Anna C.
Papp, Viktoria
Illes, Zsolt
-
Funding
Funding for this research was provided by:
University of Southern Denmark
- License Information
-
More Information
Article History
Received: 6 August 2025
Accepted: 13 December 2025
First Online: 13 January 2026
Declarations
:
: The Regional Ethical Committee (file no.: S-20200178) approved the study. The Danish Health and Medicines Authority waived the requirement for patient informed consent (file no.: 21/8187).
: Viktoria Papp received travel grants from Merck and Sanofi and received research support from Roche. Finn Sellebjerg has served on scientific advisory boards for, served as consultant for, received support for congress participation or received speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, Lundbeck, Merck, Novartis, Roche, and Sanofi Genzyme. His laboratory has received research support from Biogen, Merck, Novartis, Roche, and Sanofi Genzyme. Zsolt Illes received speakers’ honoraria and/or research grants from Biogen, Roche, Sanofi, Novartis, Merck, Alexion, Bristol Myers Squibb, Lundbeckfonden, Jascha Fonden, Scleroseforeningen, has been member of advisory boards at Alexion, Biogen, Sanofi, Merck, Roche, Novartis, has been member of adjudication relapse (clinical endpoint) committees in phase 3 trials, and has been principal investigator in studies sponsored by Biogen, Merck, and Sanofi. Melinda Magyari has served on scientific advisory board, as consultant for, received support for congress participation or speaker honoraria from Biogen, Sanofi, Roche, Novartis, Merck, Alexion, Bristol Myers Squibb. Sepehr Mamoei, Helle B. Søndergaard, Rasha Saleem, Anna C. Nilsson and Sören Möller have nothing to declare. Kristina B. Svendsen served as a consultant for Takeda and Merck, received travel grants from TEVA, Biogen, Merck, Sanofi and Novartis, and has been principal investigator in studies sponsored by Alexion, Roche, Sanofi, Novartis, and Amgen. Jette Frederiksen has received no funding to support the presented work. She has served on scientific advisory boards for and received funding for travel related to these activities as well as honoraria from Merck Serono, Sanofi-Aventis, Novartis, Alexion, and Neuraxpharm.
